Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
McAleer, Long et al. generated a reconfigurable body-on-a-chip system with recirculating medium to analyse organ function in response to anticancer drugs in real-time, which can help to improve preclinical drug testing.
Ligorio, Sil et al. used a combination of single-cell RNA and proteomic techniques in both model systems and human pancreatic ductal adenocarcinomas (PDACs) to better understand the interplay between cancer cells and fibroblasts, and the implications of this for PDAC progression.
Habets, de Bock et al. show that T cell acute lymphoblastic leukaemia (T-ALL) cells only express a subclass of γ-secretase complexes. Selective inhibition of this subclass impaired NOTCH1 processing and showed therapeutic efficacy with minimal toxicity in preclinical models of T-ALL.
Paediatric solid tumours are known to be divergent from adult malignancies. This Review describes the molecular landscape of paediatric solid tumours, the therapeutic vulnerabilities that can be targeted and the preclinical models available to test the efficacy of investigational drugs with a view to accelerating translational progress.
This Review discusses the diverse effects of senescence and the senescence-associated secretory phenotype (SASP) on tumour growth, focusing on the functional and sometimes opposing outputs of the SASP in stromal cells and incipient tumour cells.
The transcriptional activators YAP and TAZ have been discussed mainly for their cell-autonomous functions in cancer. Recent studies suggest their emerging roles in orchestrating tumour–stroma interactions, acting as a signalling hub, as discussed in this Review article.
To date, very few actionable tumour-specific antigens (TSAs) have been identified that have successfully translated into therapeutic cancer vaccines. This Opinion article provides both examples of TSAs alternative to the traditional single-nucleotide variant neoantigens and details about the novel computational tools used to identify them, with the view to broaden the number of targetable antigens that can be used for cancer vaccine development.
